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information for patients over age 65 with at least one diagnosis for Crohn’s dis-
ease. Patients who initiated therapy with tumor necrosis factor (TNF) and non-
TNF agents were identified. We examined the treatment patterns such as
switching to another TNF, switching to a non-TNF, and discontinuation for two
years after the initiation of TNF biologics. We created a data visualization tool
help visualize how patients change their treatment patterns after first and sec-
ond switches. RESULTS: A total of 3287 Crohn’s disease patients initiated therapy
with a TNF medication. 4.23% of these patients switched to another TNF, 1.00%
switched to a non-TNF, 60.42% discontinued therapy and 34.35% continued
their initial therapy. Among patients who switched to another TNF, 48.20%
continued the switched therapy, 41.01% discontinued, 10.07% switched to an-
other TNF, and 0.72% switched to a non-TNF. A total of 2,140 Crohn’s disease
patients initiated their therapy with a non-TNF, of which 0.89% switched to an
anti-TNF, 0.37% switched to a TNF, 97.38% discontinued therapy, and 1.36%
continued their initial therapy. CONCLUSIONS: When analyzing subsequent
years and switches, treatment patterns can be difficult to capture. Data visual-
ization tools can help present these complicated flows effectively for a diverse
health outcomes research audience.
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OBJECTIVES: Somepatients on prescription proton pump inhibitors (PPIs) continue
to experience breakthrough gastroesophageal reflux disease (GERD) symptoms and
use supplemental over the counter (OTC)medications. This study aimed to identify
factors associatedwith experience of breakthrough symptoms andOTCuse among
prescription PPI users. METHODS: A patient/physician survey and chart review
was conducted in GERD patients currently taking a prescription PPI. Patient [age,
gender, race, body mass index (BMI)], GERD (current severity, years since diagno-
sis), and PPI (directions to take 30-60 minutes prior to eating, daily dose, dosing
frequency) characteristics in addition to self-reported patient behaviors [actually
taking PPIs 30-60 minutes prior to eating; count of missed doses, and doses taken,
but not taken according to directions out of last 10) were considered for model
selection for OTC use and breakthrough symptoms. RESULTS: A total of 501 pa-
tients with mean age 51 years, 37% male, 81% Caucasian, 38% with college degree,
and 16% erosive versus 56% nonerosive GERD (28% undocumented) were enrolled
in the study. Overall, 40%ofpatients reported takinganOTCmedication inaddition to
their PPI. While experiencing breakthrough symptoms was the only significant pre-
dictor of OTC use (OR 5.53, p0.001), nonadherence to directions was associated with
a 14% increase in likelihood of OTC use (p0.07). Seventy-three percent of patients
reported experiencing1 breakthrough symptom. Overweight (OR/CI: 0.50/0.29-0.86)
and obese (OR/CI: 0.57/ 0.34-0.96) patients were less likely to report breakthrough
symptoms compared to normal/underweight patients, while a 1 unit increase in
missed doses was associated with a 41% increased likelihood of breakthrough symp-
toms.Nonadherence todirectionsand timesincediagnosisweresignificantpredictors
inbivariate comparisons, but lost significance in logisticmodels.CONCLUSIONS:This
study suggests real-world patient-reported medication adherence may be associ-
ated with fewer breakthrough symptoms. This highlights the importance and the
impact of medication-taking behavior on patient outcomes.
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OBJECTIVES: Published evidence on the prevalence of non-steroidal anti-inflam-
matory drug (NSAID) and gastroprotective agent (GPA) use in the United States (US)
is lacking. We examined the prevalence of GPA use among arthritis patients using
NSAIDs.METHODS: Aweb-based community panel of men and women age40 in
theUnited Stateswith self-reported arthritiswas invited via e-mail to participate in
a web-based survey. Panelists interested in participating provided consent and
completed the survey. Only participantswho reported using anNSAID in the last 30
days were eligible. Questions regarding NSAID and GPA use (medication/dosage/
frequency/duration of use) were asked, as were comorbid conditions, gastrointes-
tinal history, and other risk factors. RESULTS: Two thousand met the inclusion
criteria and completed the survey (54% response rate). Themajority of participants
had osteoarthritis (n1525, 76%), 354 (18%) had rheumatoid arthritis, and 121 (6%)
had both. Mean age was 62.0 years; 64% were female; 83% were Caucasian; 25%
worked full-time and 39% were retired. The majority (92%) had health insurance,
with half covered by Medicare/Medicaid. Mean time with arthritis was 13.0 years;
47% and 19% experienced arthritis symptoms “daily” and “almost always”, respec-
tively. The most frequently-used NSAIDs were ibuprofen (54%), aspirin (35%) and
naproxen (33%). Nearly 43% reported using a GPA with 86% (n731) reporting use
more often than three times per month. The most frequently-used GPAs were
omeprazole (48%), ranitidine (17%) and esomeprazole (17%). Of daily NSAID users,
42% reported taking a GPA. Of non-GPA users, 12% reported a history of gastro-
esophageal reflux disease, 9% reported a history of ulcers, and 3% reported a his-
tory of gastrointestinal bleeding. CONCLUSIONS: This is the first study in the
United States to document NSAID and GPA use. Importantly, only 42% of daily
NSAID users take GPAs on a routine basis, leaving the majority of NSAID users at
risk for gastrointestinal complications.
GASTROINTESTINAL DISORDERS – Cost Studies
PGI9
IMPACT OF SWITCHING PATIENTS FROM TWICE DAILY PROTON PUMP
INHIBITORS TO ONCE DAILY DEXLANSOPRAZOLE
Parthan A1, Mody RR2, Deflin MM1, Akhras KS2
1OptumInsight, Medford, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL,
USA
OBJECTIVES: Dexlansoprazole, a once-daily proton pump inhibitor (PPI) in a Dual
Delayed Release formulation has demonstrated efficacy in a phase 3b study in
maintaining symptom control among gastroesophageal reflux disease (GERD) pa-
tients previously controlled on twice daily (BID) PPIs. A pharmacy budget impact
model (BIM) from a US payer perspective was developed to assess the impact of
switching GERD patients from BID PPIs to QD dexlansoprazole over a three-year
period. METHODS: An excel-based BIM on a hypothetical plan of 1 million mem-
bers was developed. Based on published literature, 28% of members had GERD,
among which 57% were prescribed PPI therapy. Among these, 74%, 23% and 3% of
patientswere onQD, BID and as needed PPI therapy, respectively. The proportion of
patients switching from BID PPI to QD dexlansoprazole and efficacy of dexlanso-
prazole in achieving symptom control among those patientswas assumed to range
from 84%-88% based on the results of the phase 3b trial. Market share of PPIs and
drug costs were derived using internally available data. The market share of dex-
lansoprazole in year 1 was 4.23% and 8.44% pre- and post-switching, respectively.
Model outcomes for years 1, 2 and 3 included: net total and permember per month
(PMPM) pharmacy savings. RESULTS: The net pharmacy saving from switching to
QD dexlansoprazole was estimated to be $7.9, $6.4 & $5.9 million for years 1, 2, & 3,
respectively. PMPM pharmacy cost savings ranged from $0.66 in year 1 to $0.50 in
year 3. The model results were most sensitive to cost of esomeprazole, proportion
of GERD patients on PPI, prevalence of the disease, and proportion of patients
switching from BID esomeprazole to QD dexlansoprazole. CONCLUSIONS: Based
on the economic model, switching GERD patients from twice daily PPIs to QD dex-
lansoprazole may generate cost savings for US health plans.
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OBJECTIVES: Highly effective biologic therapies offer new treatment options for
patients suffering from moderate to severe ulcerative colitis (UC) who fail with
conventional therapies. A budget impact model was constructed to estimate the
costs of infliximab therapy for steroid-dependent, steroid-refractory and acute UC
patients in the perspective of Croatia. METHODS: Using epidemiology data and
medical treatment guidelines, a budget impactmodel was constructed to calculate
the annual cost of infliximab according to the Croatian Guidelines for Treatment of
UC. Moderate to severe UC patients that were diagnosed steroid-dependent, and
acute or steroid-refractory patients that were non-responsive to IV corticosteroids
were considered eligible for infliximab. Clinical trial data was applied to the guide-
lines to determine infliximab eligible patients. Sensitivity analysis was conducted
to describe the ranges of costs by varying incidence, and dosing, considering drug
wastage. RESULTS: According to the epidemiology data, 17.8% (411 patients) of all
UC patients fall into these 3 categories of patients and should be treated with
infliximab. Total costs of treating these patients according to drafted guidelines
would be 33,822,366 kn (0.01% of GDP, 0.13% of total healthcare costs or 0.50% of
total pharmaceutical sales for 2010), 19,329,407 kn (57.15%) of which is attributed to
steroid-dependent patients, 7,893,089 kn (23.34%) to steroid-refractory and
6,599,870 kn (19.51%) to acute patients. New patients who require 8 infusions
within the first year account for 11% of the cost, whereas maintenance therapy
patients receiving 6 infusions explain the rest. Adjusting the dosage from400mg/kg
to 350mg/kg decreases the total cost by 12.50% (4,227,796 kn). A decreasing inci-
dence of UC patients from 5.9 to 3.9 per 100,000 reduces the cost by 4.69% (1,586,046
kn). CONCLUSIONS: Given the significant improvement in quality of life of those
with UC, infliximab should be considered where the budget allows it. Steroid-
refractory UC patients accounted for majority of the costs.
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OBJECTIVES: To evaluate the costs associated with the treatment of Hepatitis C
Virus (HCV) treated with Peg-interferon Alpha-2a versus Peg-Interferon Alpha 2b.
METHODS: For an initial distribution of patients it was used as an assumption that
60% of patients had chronic hepatitis and the other had compensated hepatitis.
With this information was developed a Markovmodel with probabilities of disease
evolution. The stages for thismodel from this were: liver cancer, ascites, refractory
ascites, gastrointestinal bleeding, hepatic encephalopathy, liver transplantation
and death. Costs are expressed in US dollars. RESULTS: The highest response rates
were foundwith Peg-Interferon Alpha-2a for genotypes 1, 2 and 3 with a difference
up to 15% compared to Peg-Interferon Alpha-2b. Due to a higher sustained virolog-
ical response rate with Peg-Interferon Alpha-2a, the percentage of patients using
this treatment had a lower probability of falling and developing chronic complica-
tions of the disease. Therefore, the cost of the disease treatment decreases. Also
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